DE69918590D1 - Substituierte Karbazole, Verfahren zu ihrer Herstellung und ihre Verwendung als sPLA2-Inhibitoren - Google Patents

Substituierte Karbazole, Verfahren zu ihrer Herstellung und ihre Verwendung als sPLA2-Inhibitoren

Info

Publication number
DE69918590D1
DE69918590D1 DE69918590T DE69918590T DE69918590D1 DE 69918590 D1 DE69918590 D1 DE 69918590D1 DE 69918590 T DE69918590 T DE 69918590T DE 69918590 T DE69918590 T DE 69918590T DE 69918590 D1 DE69918590 D1 DE 69918590D1
Authority
DE
Germany
Prior art keywords
processes
preparation
spla2 inhibitors
substituted carbazoles
carbazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918590T
Other languages
English (en)
Other versions
DE69918590T2 (de
Inventor
Nicholas James Bach
Jolie Anne Bastian
Gary Alan Hite
Michael Dean Kinnick
Edward David Mihelich
John Michael Morin Jr
Daniel Jon Sall
Robert Theodore Vasileff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69918590D1 publication Critical patent/DE69918590D1/de
Application granted granted Critical
Publication of DE69918590T2 publication Critical patent/DE69918590T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69918590T 1998-04-17 1999-04-16 Substituierte Karbazole, Verfahren zu ihrer Herstellung und ihre Verwendung als sPLA2-Inhibitoren Expired - Lifetime DE69918590T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17
US62328 1998-04-17

Publications (2)

Publication Number Publication Date
DE69918590D1 true DE69918590D1 (de) 2004-08-19
DE69918590T2 DE69918590T2 (de) 2005-07-21

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69917833T Expired - Lifetime DE69917833T2 (de) 1998-04-17 1999-04-16 Substituierte Karbazole, Verfahren zu ihrer Herstellung und ihre Verwendung als sPLA2- Inhibitoren
DE69918590T Expired - Lifetime DE69918590T2 (de) 1998-04-17 1999-04-16 Substituierte Karbazole, Verfahren zu ihrer Herstellung und ihre Verwendung als sPLA2-Inhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69917833T Expired - Lifetime DE69917833T2 (de) 1998-04-17 1999-04-16 Substituierte Karbazole, Verfahren zu ihrer Herstellung und ihre Verwendung als sPLA2- Inhibitoren

Country Status (30)

Country Link
EP (2) EP0952149B1 (de)
JP (2) JPH11322713A (de)
KR (2) KR100586761B1 (de)
CN (1) CN1149193C (de)
AR (2) AR018186A1 (de)
AT (2) ATE268756T1 (de)
AU (2) AU753547B2 (de)
BR (2) BR9902365A (de)
CA (2) CA2269262A1 (de)
CO (2) CO5011054A1 (de)
CZ (2) CZ137099A3 (de)
DE (2) DE69917833T2 (de)
DK (1) DK0950657T3 (de)
DZ (1) DZ2769A1 (de)
EA (2) EA002347B1 (de)
ES (2) ES2222663T3 (de)
HU (2) HUP9901221A3 (de)
ID (2) ID23761A (de)
IL (2) IL129485A0 (de)
NO (2) NO312240B1 (de)
NZ (3) NZ507564A (de)
PE (2) PE20000432A1 (de)
PL (2) PL332565A1 (de)
PT (1) PT950657E (de)
SG (2) SG81977A1 (de)
SI (1) SI0950657T1 (de)
TR (2) TR199900843A2 (de)
TW (1) TWI238160B (de)
YU (2) YU18999A (de)
ZA (2) ZA992772B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
DE60032774D1 (de) * 1999-07-19 2007-02-15 Lilly Co Eli Spla2 inhibitoren
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
DE60130891T2 (de) * 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
WO2002000256A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
WO2002000257A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for alzheimer's disease
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
AU2002239263A1 (en) 2000-12-18 2002-07-01 Eli Lilly And Company Tetracyclic carbazole derivates and their use as spla2 inhibitors
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (de) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Neue Tetrahydrocarbazolderivate als Liganden von G-Protein-gekoppelten Rezeptoren
WO2009119534A1 (ja) 2008-03-26 2009-10-01 第一三共株式会社 新規テトラヒドロイソキノリン誘導体
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US8580795B2 (en) 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
WO2014083163A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
RU2015118217A (ru) 2012-11-30 2017-01-11 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ кристаллизации трициклических индольных производных
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
JPH06509087A (ja) * 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
EP0749962B1 (de) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
DE69614232T2 (de) * 1995-12-13 2002-01-10 Eli Lilly And Co., Indianapolis Naphthyl-Acetamide als sPLA2-Inhibitoren
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
JP2001522884A (ja) * 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
PE20000476A1 (es) 2000-06-02
EP0952149B1 (de) 2004-06-09
NO314400B1 (no) 2003-03-17
NZ335251A (en) 2000-11-24
ES2222663T3 (es) 2005-02-01
YU18999A (sh) 2002-08-12
CO5011054A1 (es) 2001-02-28
NZ335253A (en) 2000-11-24
BR9902365A (pt) 2001-04-24
TR199900843A2 (xx) 2000-02-21
NZ507564A (en) 2002-10-25
AU753436B2 (en) 2002-10-17
ES2226286T3 (es) 2005-03-16
EP0950657A2 (de) 1999-10-20
AR018186A1 (es) 2001-10-31
HU9901220D0 (en) 1999-06-28
HUP9901221A3 (en) 2001-11-28
ATE271037T1 (de) 2004-07-15
AU753547B2 (en) 2002-10-24
CO5031247A1 (es) 2001-04-27
TWI238160B (en) 2005-08-21
EA199900301A3 (ru) 2000-04-24
CZ137099A3 (cs) 1999-11-17
PL332566A1 (en) 1999-10-25
EA199900301A2 (ru) 1999-10-28
HUP9901220A3 (en) 2001-11-28
NO312240B1 (no) 2002-04-15
DZ2769A1 (fr) 2003-12-01
HU9901221D0 (en) 1999-06-28
ZA992771B (en) 2002-04-18
ID23287A (id) 2000-04-05
JP4435330B2 (ja) 2010-03-17
DK0950657T3 (da) 2004-11-22
PE20000432A1 (es) 2000-05-23
DE69917833D1 (de) 2004-07-15
AU2381799A (en) 1999-10-28
NO991821L (no) 1999-10-18
TR199900853A3 (tr) 1999-11-22
SI0950657T1 (en) 2005-02-28
IL129485A0 (en) 2000-02-29
ZA992772B (en) 2002-07-16
PL332565A1 (en) 1999-10-25
CA2269262A1 (en) 1999-10-17
SG81976A1 (en) 2001-07-24
KR19990083233A (ko) 1999-11-25
HU9901221A (hu) 2000-04-28
BR9901279A (pt) 2000-05-02
JPH11322713A (ja) 1999-11-24
KR100586761B1 (ko) 2006-06-08
TR199900853A2 (xx) 1999-11-22
NO991822D0 (no) 1999-04-16
EA002816B1 (ru) 2002-10-31
CN1253948A (zh) 2000-05-24
IL129483A0 (en) 2000-02-29
AR018593A1 (es) 2001-11-28
DE69918590T2 (de) 2005-07-21
EP0950657A3 (de) 2001-08-16
CZ136999A3 (cs) 1999-11-17
JP2000026416A (ja) 2000-01-25
DE69917833T2 (de) 2005-07-14
PT950657E (pt) 2004-11-30
AU2381999A (en) 1999-10-28
CA2269246A1 (en) 1999-10-17
NO991821D0 (no) 1999-04-16
KR19990083232A (ko) 1999-11-25
YU19199A (sh) 2002-08-12
SG81977A1 (en) 2001-07-24
CA2269246C (en) 2009-08-25
EA199900303A2 (ru) 1999-10-28
NO991822L (no) 1999-10-18
EA199900303A3 (ru) 2000-04-24
ATE268756T1 (de) 2004-06-15
CN1149193C (zh) 2004-05-12
EA002347B1 (ru) 2002-04-25
EP0952149A2 (de) 1999-10-27
EP0952149A3 (de) 2001-08-16
HU9901220A (hu) 2000-04-28
EP0950657B1 (de) 2004-07-14
ID23761A (id) 2000-05-11

Similar Documents

Publication Publication Date Title
DE69917833D1 (de) Substituierte Karbazole, Verfahren zu ihrer Herstellung und ihre Verwendung als sPLA2- Inhibitoren
DE60033028D1 (de) 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung
DE69925145D1 (de) 2-aminothiazolederivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DE69922086D1 (de) Funktionsangepasste Legierung, ihre Verwendung und Verfahren zu ihrer Herstellung
DE50208960D1 (de) Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
DE10393704D2 (de) Nancomposite, Verfahren zu ihrer Herstellung und ihre Verwendung
DE10399006I2 (de) Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE122006000035I2 (de) Nd verfahren zu seiner herstellung
DE69927427D1 (de) Mit Silan oberflächenbehandelte Kieselsäureteilchen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69708411D1 (de) Phosphite, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE327981T1 (de) Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
DE59913771D1 (de) Beschichtungsmittel und Klebstoffe, ihre Verwendung und Verfahren zu ihrer Herstellung
DE69706690D1 (de) Acryloyl-substituierte distamycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor- und antivirale mittel
DE50008845D1 (de) Substituierte benzoylketone, verfahren zu ihrer herstellung und ihre verwendung als herbizide
DE69819457D1 (de) Phosphorsäureester, Verfahren zu seiner Herstellung und Verwendung davon
DE59610666D1 (de) Mehrlagenfolie, verfahren zu ihrer herstellung und ihre verwendung
DE69908371D1 (de) Thioethergruppen enthaltende distamycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DE60032381D1 (de) Polierzusammensetzung und verfahren zu ihrer verwendung
DE69922378D1 (de) Oxidierte sulfurierte distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DE60116063D1 (de) Memno-peptide, verfahren zu ihrer herstellung und ihre verwendung
DE59908394D1 (de) Wasserlösliche Monoazoverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Farbstoffe
DE59800568D1 (de) Benzoxazindionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE50107787D1 (de) Acesulfam-Metall-Komplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
DE59700950D1 (de) 5-Z-Octenylester, Verfahren zu ihrer Herstellung und ihre Verwendung
DE59905337D1 (de) Steroidhaltiges pflaster, verfahren zu seiner herstellung und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN